Alcohol giant Constellation Brands Inc. is making a foray into marijuana, a precedent-setting move for an industry that has mostly stayed on the sidelines during the cannabis boom.
Constellation will pay about $191 million for a 9.9 percent stake in Canopy Growth Corp., a Canadian seller of medicinal-marijuana products. The deal kicked off the biggest rally in nearly a year for Canopy, which trades on the Toronto Stock Exchange under the ticker WEED.
The legalization of marijuana in Canada and a growing number of U.S. states is opening up a huge potential market – just as demand for alcohol is slowing. Still, pot remains prohibited at the U.S. federal level, meaning American companies have to tread carefully.
Constellation, based in Victor, New York, said it has no plans to sell cannabis in the U.S. or other markets until it’s legal “at all government levels.” For now, it’s more a matter of identifying markets with growth potential, said Chief Executive Officer Rob Sands, whose company sells Corona beer, Svedka vodka and other brands.
“Our company’s success is the result of our focus on identifying early-stage consumer trends, and this is another step in that direction,” he said in a written statement.
For Canopy, the deal values the business at roughly $2.5 billion (Canadian), catapulting it into the highest echelons of the marijuana industry. Constellation also would become the company’s biggest shareholder. Canopy’s stock gained as much as 23 percent Monday, marking its biggest intraday jump since November 2016.
The transaction also boosted the shares of other cannabis stocks, as investors bet that future deals are in the offing. Shares of MedReleaf Corp. rose as much as 16 percent, Aurora Cannabis Inc. gained 8.4 percent, and Aphria Inc. was up 11 percent.
As part of the Constellation agreement, the two companies will collaborate on cannabis-based beverages that can be sold as adult products – but only in places where the products are legal at the federal level.
Canada plans to legalize recreational marijuana by July 2018, but the initial product offerings will be limited, said Bruce Linton, Canopy’s CEO. Edibles and cannabis-infused beverages won’t be permitted at the outset.
That will change in the coming years as Canada moves to extinguish the black market and these products will be phased in over time, he said.
“This looks a lot like the new normal,” Linton said by phone, noting that Canopy and Constellation have a “blank sheet” to create cannabis-infused beverages. “There’s no need to include alcohol, nor is there an intent to include alcohol in how we follow through with things.”
In the U.S., meanwhile, 64 percent of the population now wants to lift the ban on cannabis, according to a Gallup poll released last week. That’s the widest margin since the firm began asking about the topic in 1969, when only 12 percent of the population approved.
Eight states, including Maine, and Washington, D.C., have legalized marijuana for adult use. That means one in five Americans over the age of 21 are allowed to eat, drink, smoke or vape cannabis – even though it remains illegal at the federal level. Twenty-one states, including Maine, allow it for medicinal purposes. The legal cannabis market was $6 billion last year and is expected to reach $50 billion by 2026, according to Cowen & Co.
The Constellation deal includes warrants that will let it eventually double its stake. The purchase is expected to close during the company’s third fiscal quarter.
“We see this transaction as a game-changer for Canopy, as well as the industry at large,” Beacon Securities analyst Vahan Ajamian said in a note.
The Constellation transaction could be the first of many, he said.
“We suspect more alcohol companies may look to accelerate plans to enter the industry – as well as pharmaceutical and tobacco companies,” he said.
Send questions/comments to the editors.
